Results 221 to 230 of about 101,527 (239)
Some of the next articles are maybe not open access.
Cyclooxygenase inhibitors: drugs for cancer prevention
Current Opinion in Pharmacology, 2003Evidence that chronic intake of non-steroidal anti-inflammatory drugs, especially aspirin, prevents cancer development continues to accumulate. The data are particularly convincing for colorectal cancer; however, because of well-known side effects, they cannot routinely be recommended for this purpose.
Santini Dl +2 more
openaire +3 more sources
Cyclooxygenase-2 Inhibitors in Glioma Therapy
American Journal of Therapeutics, 2004The cyclooxygenase enzyme is a prostaglandin synthase that has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Upregulation of the COX-2 isoform in many cancers has led to investigation regarding the potential role of this enzyme in oncogenesis.
Victor A. Levin, Pierre Giglio
openaire +3 more sources
Selective cyclooxygenase-2 inhibitors
La Presse Médicale, 2005Resume Objectifs L’utilisation des inhibiteurs selectifs de la cyclo-oxygenase 2 (coxibs) est actuellement contestee, en particulier en raison des risques cardiovasculaires. Peu de travaux ont evalue leurs conditions reelles d’utilisation. Cette etude avait pour buts de mesurer l’evolution des conditions reelles d’utilisation des coxibs en France et
Guy-Robert Auleley +3 more
openaire +2 more sources
New cycloalkylpyrazoles as potential cyclooxygenase inhibitors
Il Farmaco, 1998AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
CARDIA, MARIA CRISTINA +5 more
openaire +5 more sources
Selective Cyclooxygenase Inhibitors: Current Status
Current Drug Discovery Technologies, 2014For ages aspirin has established its value as an analgesic, anti-inflammatory drug, but in 1938, it was found to be a causative factor of gastric inflammation (ulcer). Later discovered non-steroidal anti-inflammatory drugs (NSAIDs) were found effective as aspirin but failed to overcome the goal of safer aspirin.
Malepati Rajapranathi +3 more
openaire +3 more sources
Selective inhibitors of cyclooxygenase-2
Expert Opinion on Therapeutic Patents, 1997Prostaglandins (PGs) produced by the inducible enzyme cyclooxygenase-2 (COX-2) are important mediators of pain and inflammation. In animals, selective inhibitors of COX-2 have been shown to be anti-inflammatory without typical non-steroidal anti-inflammatory drug (NSAID) side-effects. Research directed towards the identification of potent and selective
openaire +2 more sources
Pharmacology and efficacy of cyclooxygenase (COX) inhibitors
The American Journal of Medicine, 1999Discussion of the pharmacology and efficacy of cyclooxygenase (COX) inhibition requires careful attention to the methodology used for making those comparisons. In vitro analysis of COX-2/COX-1 ratios requires consideration of the target tissues being examined, the details of incubation periods, outcome measures, and other parameters.
openaire +3 more sources
Cardiovascular effects of cyclooxygenase-2 inhibitors
Current Opinion in Internal Medicine, 2008Arthritis and musculoskeletal disorders are highly prevalent and management often involves the use of nonsteroidal antiinflammatory drugs. Cyclooxygenase-2 enzyme inhibitors are newer selective nonsteroidal antiinflammatory drugs that purport to exhibit less gastrointestinal toxicity than traditional nonsteroidal antiinflammatory drugs.
openaire +3 more sources
The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness
Annals of Pharmacotherapy, 1999OBJECTIVE: To review the development of cyclooxygenase-2 (COX-2) inhibitors and discuss specific agents that are currently under investigation or have been marketed. DATA SOURCES: Primary literature on selective COX inhibitors was identified from a comprehensive MEDLINE, English-literature search from January 1966 through September 1998, with ...
Barbara Storyk Klostermeyer +1 more
openaire +2 more sources
Cyclooxygenase-2 inhibitors and cardiovascular risk
Current Opinion in Cardiology, 2006Cyclooxygenase-2 inhibitors, or coxibs, designed to provide comparable pain relief to traditional nonsteroidal anti-inflammatory drugs with reduced risk of gastrointestinal complications, have come under substantial recent scrutiny because of an increased likelihood of adverse cardiovascular events associated with their use.Data concerning the ...
openaire +3 more sources